MedTrace Logo

The POWERED Study: Prophylaxis With Metformin to Prevent PTDM

NCT05240274 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-10-18

No results posted yet for this study

Summary

PrOphylaxis With mEtformin to pREvent PTDM: a single site, placebo controlled, double blind randomised clinical trial evaluating the effectiveness of metformin to prevent post-transplant diabetes in a cohort of patients undergoing renal transplantation.

Conditions

  • Post-transplant Diabetes Mellitus
  • New Onset Diabetes After Transplant
  • New Onset Diabetes After Transplantation
  • Kidney Transplant; Complications
  • Renal Transplantation
  • End Stage Renal Disease
  • Metformin

Interventions

DRUG

Metformin

metformin 500mg OD for 3 months to start within 10 days post-renal transplant

DRUG

Placebo

placebo 500mg OD for 3 months to start within 10 days post-renal transplant

Sponsors & Collaborators

  • Barts & The London NHS Trust

    lead OTHER

Principal Investigators

  • Kieran McCafferty, M.B., B.Chir · Barts Health NHS Trust; Queen Mary University London

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-25
Primary Completion
2022-05-30
Completion
2022-08-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05240274 on ClinicalTrials.gov